Therapeutic efficacy and related factors of entecavir treatment for patients with acute on chronic hepatitis B liver failure
10.3760/cma.j.issn.1674-2397.2011.01.004
- VernacularTitle:恩替卡韦治疗慢加急性乙型肝炎肝衰竭的疗效和预测因素研究
- Author:
Bingliang LIN
;
Dongying XIE
;
Xiaohong ZHANG
;
Junqiang XIE
;
Shaoquan ZHANG
;
Yutian CHONG
;
Zhiliang GAO
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Liver failure;
Entecavir;
Therapy
- From:
Chinese Journal of Clinical Infectious Diseases
2011;04(1):21-24
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the therapeutic efficacy and its related factors of entecavir treatment for patients with acute on chronic hepatitis B liver failure (ACHBLF).Methods One hundred and eight patients with ACHBLF were enrolled and divided into entecavir group (n=53) and control group (n=55).HBV DNA level, liver function and 48-week survival rate were observed, and C ox regression model was established to identify the factors which may affect the efficacy of entecavir treatment.Results Totally 70 patients died in the study and 66 died within 12 weeks.The statistical difference on cumulative survival rate between two groups was observed from the third week on (χ2=5.357, P ＜ 0.05).The 48-weekcumulative survival rate in entecavir group was 47.2% (25/53), while that in the control group was 23.6%(13/55) (χ2=7.432, P ＜ 0.01).In entecavir group, for patients aged ＜ 40 with serum bilirubin level ＜513 μnol/L and international normalized ratio (INR) ＜ 2.5, the fatality rates decreased 74.9%, 75.3%and 76.0%, respectively.Conclusions Entecavir may improve the survival rate of patients with ACHBLF.Age, serum bilirubin level and INR are major factors related to the therapeutic efficacy.
